THTX צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Theratechnologies Inc

The quarterly earnings per share dynamics of Theratechnologies Inc. (THTX) correlate with revenues from HIV and oncology drug sales, where the value -552.80 represents the current figure. Efficiency is increasing through AI-driven automation of peptide synthesis. Patent protection in the lipodystrophy niche within the US market guarantees the issuer a sustainable operating margin and business stability.
Theratechnologies Inc. - פילוחים אנליטיים ומדדי מפתח (THTX)

For Theratechnologies Inc., which is developing drugs to combat HIV and cancer, this indicator serves as a leading signal of business efficiency. The metric measures the rate of change in net earnings per share on a quarterly basis. By analyzing the quarterly EPS growth rate, an investor can see the real monetization dynamics of niche medications. A downward trend on the chart warns of slowing profit growth, while a stable vector confirms the resilience of the company's pharmaceutical capacities.